Buy or sell HistoSonics stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

HistoSonics Stock

Developing a non-invasive, autonomous robotic platform capable of destroying tissue at a sub-cellular level

About HistoSonics Stock

HistoSonics, Inc. was created to advance the development of histotripsy, a science discovered and developed by leading scientists at the University of Michigan to provide improved therapies for patients. According to the company, its exclusive license to intellectual property, significant financial support, and strategic partnerships have helped HistoSonics develop Robotically Assisted Sonic Therapy (RAST)™, a novel beam therapy capable of destroying tissue at a sub-cellular level. HistoSonics’ team of specialists and industry leaders is based in Ann Arbor, Michigan.

Funding History

February 2010$14.0M
May 2014$0
December 2014$1.5M
September 2015$3.5M
March 2017$8.3M
July 2018$4.8M
April 2019$54.0M

Management

VP of Regulatory & Clinical Affairs

Michael Daniel

CFO

Jon Freeman

VP of Research & Development

Joshua Stopek

VP of Operations

Daniel Bulver

President & CEO

Mike Blue

VP of Marketing

Josh King

Other Companies

EquityZen does not have an affiliation with, formal relationship with, or endorsement from HistoSonics or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 100K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

LogoLogo